Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663192 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL25484875 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL25764647 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL22284357 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| Hydrochloric Acid SCHEMBL7399417 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL13197107 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL458805 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL15140566 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL20780854 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL6418803 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | ZIKANI THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4358970-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | Zikani Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022251730-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | UPF1, RRP1B, REV1 | SMN1; SMN2 228/4885CYP2C19 3106/4885NPC1 627/4885 |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | MALT1, NR3C2, MRPL21 | SMN1; SMN2 1523/4885CYP2C19 589/4885NPC1 110/4885 |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL17, RPN2 | SMN1; SMN2 1399/4885CYP2C19 334/4885NPC1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.